Can a new drug combo tame resistant prostate cancer?
Disease control
Recruiting now
This phase 2 trial is testing whether an investigational oral drug called MRT-2359, when combined with the standard prostate cancer drug apalutamide, can lower PSA levels in men with castration-resistant prostate cancer. The study includes about 25 adults with a specific genetic …
Phase 2 • Sponsor: Monte Rosa Therapeutics, Inc • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC